Lekarze w zakresie PET-CT za granicą — Strona 4

Lekarz jest wybitnym austriackim onkologiem klinicznym i internistą z ponad dwudziestoletnim doświadczeniem, specjalizującym się w raku piersi, nowotworach ginekologicznych i celowanych terapiach nowotworowych. Absolwent Uniwersytetu Wiedeńskiego, lekarz ukończył rezydenturę z zakresu chorób wewnętrznych i onkologii klinicznej na Uniwersytecie Medycznym w Wiedniu. Lekarz przyczynił się do wczesnych badań klinicznych nad terapiami celowanymi i jest wiodącym autorytetem w dziedzinie spersonalizowanego leczenia nowotworów.<\/p>

Obecnie pełni funkcję starszego konsultanta w Wiener Privatklinik i kontynuuje pracę akademicką na Uniwersytecie Medycznym w Wiedniu, lekarz koncentruje się na spersonalizowanej terapii systemowej nowotworów, immunoterapii i badaniach translacyjnych nowotworów. Badania lekarza obejmują rozwój biomarkerów i mechanizmy oporności na leki celowane, z publikacjami w wiodących międzynarodowych czasopismach.<\/p>

Dr. Hossein Taghizadeh is a highly regarded Austrian specialist in internal medicine, hematology, and medical oncology, known for his compassionate approach and commitment to personalized cancer care. With extensive experience in treating solid tumors and blood cancers, he represents a new generation of oncologists who integrate scientific progress with empathy and precision.

He studied medicine at the Medical University of Vienna, graduating in 2016, and began his residency in internal medicine and oncology shortly thereafter. His academic and clinical training at leading Austrian cancer centers equipped him with deep expertise in systemic cancer therapy, hematologic diseases, and palliative medicine.

2010–2016 – Studied medicine at the Medical University of Vienna.

2018 – Began residency in internal medicine and medical oncology, focusing on individualized treatment strategies.

2020s – Specialized in solid tumors, hematologic malignancies, and targeted therapy, contributing to multidisciplinary oncology care.

Today – Practices as an oncologist at Oncodoc and Wiener Privatklinik, providing diagnostics, systemic treatment, and follow-up for patients with gastrointestinal, urogenital, and hematologic cancers.

Dr. Taghizadeh’s clinical interests include gastrointestinal tumors, pancreatic and biliary cancers, genitourinary malignancies, and hematologic neoplasms. He works with advanced diagnostic tools and modern systemic therapies, including chemotherapy, targeted therapy, and immunotherapy.

Known for his calm professionalism, integrity, and patient-centered communication, Dr. Taghizadeh places great emphasis on evidence-based medicine and emotional support throughout the treatment journey. His work reflects a modern, holistic approach to oncology — one that values both medical excellence and the human experience behind every diagnosis.

Lekarz specjalizuje się w chirurgii jelita grubego, trzustki i przewodu pokarmowego, z szczególną wiedzą w zakresie procedur Whipple'a. Z ponad 45-letnią praktyką, lekarz jest uznawany za jednego z wiodących chirurgów Whipple'a w Izraelu.<\/p>

Lekarz jest onkologiem specjalizującym się w leczeniu raka piersi, płuc i przewodu pokarmowego. Obecnie lekarz praktykuje w Szpitalu Uniwersyteckim Istinye Liv.

Z karierą obejmującą wiele renomowanych instytucji, lekarz pracował jako specjalista chorób wewnętrznych w Szpitalu Państwowym w Malatyi, lekarz w Klinice Onkologicznej w Ankarze oraz członek Oddziału Onkologii w Regionalnym Szpitalu Szkoleniowo-Badawczym w Erzurum.

Lekarz ukończył Wydział Medyczny Uniwersytetu Selcuk i uzyskał tytuł profesora nadzwyczajnego w 2016 roku.

Dr. Cemil Bilir is a professor of medical oncology at VM Medical Park Pendik Hospital in Istanbul. He specializes in immunotherapy and chemotherapy for lung, breast, and prostate cancers. A former research fellow at Northeastern University in Boston, he focused on pharmaceutical biotechnology and nanomedicine. Dr. Bilir works at a JCI-accredited facility where academic physicians provide around-the-clock care.

• Member of the American Society of Clinical Oncology (ASCO) and ESMO.
• Completed a specialized clinical rotation at the Cleveland Clinic in the U.S.
• Treats complex oncological cases, including stage 4 lung cancer and sarcoma.
• Current Ph.D. student in inorganic chemistry at Sakarya University.

Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.

Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.

Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.

Dr. Murat Atay is a breast and general surgeon at Istanbul Florence Nightingale Hospital. He completed specialized training in sentinel node mapping at the MDA Cancer Center in Texas. Dr. Atay also held several surgical roles at Lille University Hospital in France. He focuses on breast and thyroid surgery as well as oncological procedures.

• Performs mastectomy, lumpectomy, and lymphadenectomy.
• Treats conditions such as breast cancer and fibrocystic breast disease.
• Practices at a JCI-accredited smart hospital that treats 300,000 patients annually.
• Uses PET-MRI and mammography for precise diagnosis and monitoring.

Dr. Ercan Ozden is a medical oncologist and internal medicine specialist at VM Medical Park Pendik. He provides treatment for a wide range of cancers, including breast, lung, and colon cancer. Dr. Ozden trained at Istanbul University, Cerrahpasa Faculty of Medicine. He later completed a medical oncology subspecialty at Kocaeli University.

• Specializes in immunotherapy, target therapy, and chemotherapy for complex cases.
• Treats patients at a JCI-accredited hospital in Istanbul.
• Performs staging and biopsies for liver, lung, and pancreatic tumors.
• Provides targeted immunotherapy using medications like Keytruda.

Dr. Baha Zengel is a general surgeon at Medicalpoint International Hospital. He specializes in oncoplastic breast surgery and thyroid diseases. He holds a doctorate in Basic Oncology from Dokuz Eylül University. Dr. Zengel serves as a founding board member of the Basic Oncology Association. He works at a JCI-accredited facility in İzmir.

• Performs breast-conserving mastectomy and simultaneous reconstructions.
• Expert in ROLL and SNOLL localization techniques for non-palpable lesions.
• Treats patients using laparoscopic cholecystectomy for gallbladder diseases.
• Former board member of the Aegean Region Surgery Association.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Yan Zhi Ping is the Director of the Radiology Department at Xiamen Humanity Hospital. He graduated from the First Military Medical University. He has authored more than 30 papers. He has edited and contributed to several monographs. He received a Fujian Provincial Third Prize for Science and Technology Progress and two Xiamen Municipal Second Prizes. His expertise includes CT and MRI of the central nervous system, musculoskeletal system, thoracic, and abdominal diseases. He also focuses on cerebral functional imaging. He is skilled in the early diagnosis and differential diagnosis of lung cancer and brain tumors.

Appointments: Standing Committee Member of the Radiology Branch of the Fujian Association of Integrative Medicine. Standing Committee Member of the Fujian Radiological Society. Vice Chairman of the Xiamen Radiological Society. Vice Chairman of the Radiology Branch of the Xiamen Medical Doctor Association. Deputy Director of the Xiamen Radiology Quality Control Center.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Dr. Gul Alco is a radiation oncologist and Professor at Medipol Acibadem District Hospital in Istanbul. She excels in treating complex cases, including stage 4 lung and liver cancers. Dr. Alco utilizes the CyberKnife and Da Vinci robotic systems for precise tumor targeting. She works at a JCI-accredited facility known for its high safety standards.

• Specializes in brachytherapy and high-intensity focused ultrasound ablation (HIFU).
• Performs radiofrequency ablation and proton-beam therapy for various malignancies.
• Treats pancreatic, breast, ovarian, and brain cancers using targeted radiation.
• Expert in nuclear medicine diagnostics, including PET-CT with Gallium 68.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. LV Xiao Jun is the Executive Director of the Department of Medical Oncology. He is a national expert in psycho-oncology and has 30 years of clinical experience. He previously served at the First Affiliated Hospital of Xiamen University. He is a recognized expert in cancer treatment and lung cancer care in Fujian Province.

Clinical focus: comprehensive care for solid tumors, including lung, breast, and gastrointestinal cancers; palliative care in oncology; and screening and treatment for psychological distress.

Appointments: Standing Committee Member (third term), Psycho-Oncology Committee, Chinese Anti-Cancer Association; Standing Committee Member (third term), Lung Cancer Committee, Fujian Anti-Cancer Association.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Felix Dobritoiu is a thoracic surgeon at Ponderas Academic Hospital in Bucharest. He performs robotic thoracic surgery using the da Vinci Xi system. Dr. Dobritoiu treats both adults and children. He focuses on small-incision techniques to ensure faster patient recovery. His hospital holds JCI accreditation and acts as a Robotic Surgery Center of Excellence.

• Specializes in video-assisted thoracoscopic surgery (VATS) including uniportal techniques.
• Performs complex lung resections, mediastinoscopy, and bronchoscopy.
• Treats lung cancer, thymoma, thyroid cancer, and adenocarcinoma.
• Offers sternochondroplasty for chest wall deformities using the Nuss procedure.